Universität Regensburg

Wolfgang Herr

Anschrift:

Leistungsprofil:

• CAR-T-Zell-Therapie bei akuten Leukämien und Tumoren
• allogene Stammzelltransplantation
• Graft-versus-Leukemia
• adoptive Immuntherapie
• Tumorimmunologie

• adoptiver Transfer von Memory-T-Zellen im Kontext der allogenen Stammzelltransplantation
• adoptiver Transfer von CAR-modifizierten T-Zellen
• T-Zell-Monitoring im Rahmen von Tumorimmuntherapien

• Elispot-Methode
• HLA/Tetramer-Färbungen
• Durchflusszytometrie

Publikationen:

• Herr W, Eichinger Y, Beshay J, Bloetz A, Vatter S, Mirbeth C, Distler E, Hartwig UF, Thomas S. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation. Leukemia. 2016 Aug 1. doi: 10.1038/leu.2016.210. [Epub ahead of print].
• Thomas S, Klobuch S, Podlech J, Plachter B, Hoffmann P, Renzaho A, Theobald M, Reddehase MJ*, Herr W*, Lemmermann NA*. Evaluating human T-cell therapy of cytomegalovirus organ disease in HLA-transgenic mice. PLoS Pathog. 2015;11:e1005049. *shared senior authorship
• Schuchmann M, Meyer RG, Distler E, von Stebut E, Kuball J, Schnürer E, Wölfel T, Theobald M, Konur A, Gregor S, Schreiner O, Huber C, Galle PR, Otto G, Herr W. The programmed death (PD)-1 / PD-ligand 1 pathway regulates graft-versus-host reactive CD8 T cells after liver transplantation. Am J Transplant. 2008;8:2434-44.
• Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A, Hartwig UF, Wehler TC, Ullmann AJ, Gentilini C, Uharek L, Huber C, Kolbe K, Herr W. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007;109:374-82.
• Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig U*, Herr W*. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and anti-tumor donor T-cell lines. Blood 2007;109:365-373. *shared senior authorship
• Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W. Superior antitumor in vitro responses of allogeneic matched sibling compared to autologous patient CD8+ T cells. Cancer Res. 2006;66:11447-54.
• Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by nanoLC MALDI MS/MS. Mol Cell Proteomics 2005;4:1888-97.
• Dorrschuck A, Schmidt A, Schnurer E, Gluckmann M, Albrecht C, Wolfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, Karas M, Wolfel T, Herr W. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004;104:2591-2599.
• Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, Storkus WJ. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4+ or CD8+ T lymphocytes from human blood. Proc Natl Acad Sci USA 1999;96:12033-8.

Kooperationsangebot für die Wirtschaft / Praxis:

• klinische Translation von immuntherapeutischen Strategiekonzepten im Rahmen von Tumor- und Leukämieerkrankungen
• Habilitation
• Clinician Scientist Förderung

Bestehende Kooperationen:

Sonstiges: